Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshensu is a **natural water-soluble phenolic acid** (specifically, (R)-3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid) derived from the root of *Salvia miltiorrhiza* (danshen), a widely used traditional Chinese medicinal herb[1][2][3][4]. It possesses **antithrombotic, cardioprotective, neuroprotective, antioxidant, anti-inflammatory, and antidepressant activities**[1][3][5][6]. Its pharmacological actions are mediated through several molecular pathways, including selective cyclooxygenase-2 (COX-2) inhibition (without substantial inhibition of COX-1), normalization of thromboxane A2/prostacyclin (TXA2/PGI2) balance, activation of the PI3K/Akt/ERK/mTOR and Nrf2 signaling pathways, modulation of AMPA receptors, upregulation of brain-derived neurotrophic factor (BDNF), and calcium and potassium channel modulation[1][3][5][6]. It has shown potential in the treatment of thrombosis, myocardial ischemia/reperfusion injury, neurodegenerative conditions (e.g., Parkinson's disease, Alzheimer's disease), ischemic stroke, and depression[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danshensu.